powerpoint 프레젠테이션 · 2019-10-29 · 17 diabetes/obesity rare diseases cancer autoimmune...
TRANSCRIPT
2
3
4
5
AUG
OCT
SEP
(5.7%)
6
7
39.95.02.2
(3.4%)
8
9
10
11
12
13
14
15
16
17
Diabetes/Obesity
Rare diseases
Cancer
Autoimmune diseases
Others
B Beijing Hanmi
Pre-Clinical Phase 2 Phase 3Phase 1
LAPSGCG ComboHM14320Obesity/Diabetes/NASH
GBM Stem Cell TherapyHM21001Glioblastoma
AJOU Univ
LAPSTriple AgonistHM15211NASH
LAPSGCG AnalogHM15136Obesity/Congenital Hyperinsulinism
PD-1/CD47BH29XXTargeted Immuno-oncology
B
LAPSASBHM15450Mucopolysaccharidosis
LAPSGLP/GCGHM12525AObesity/Diabetes
LAPSIns/LAPSInsulin AnalogHM12460A/HM12470Diabetes
Pan-RAF InhibitorBelvarafenibSolid tumors
GENENTECH
PD-1/PD-L1BH2996HTargeted Immuno-oncology
B
EfpeglenatideLAPSExd4 AnalogObesity/Diabetes
SANOFI
EfpegsomatropinLAPShGHGH deficiency
Luminate®
Integrin inhibitor
DMEALLEGRO
BTK InhibitorHM71224Autoimmune disease
Pan-HER InhibitorPoziotinibSolid tumor
SPECTRUM
Rolontis™EflapegrastimNeutropenia
SPECTRUM
Oraxol™Paclitaxel+HM30181ASolid tumor
ATHENEX
PD-1/HER2BH2950Targeted Immuno-oncology
B
INNOVENT
FLT3 InhibitorHM43239
AML
TNF-α/IL-17BH1657Targeted Autoimmune diseases
B LAPSGLP-2 AnalogHM15912Short Bowel Syndrome
LAPSInsulin148HM12480Diabetes
LAPSInsulin ComboHM14220Diabetes
Luminate®
Integrin inhibitorRetinitis Pigmentosa
Oratecan™Irinotecan+HM30181ASolid tumor
Oradoxel™Docetaxel+HM30181ASolid tumor
ATHENEX
ATHENEX
A2AR antagonist
Solid tumor
LSD1 Inhibitor
SCLC, AML
SANOFI
18